Clincosm LogoSign in Get a demo

Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss

Sponsor
Bagcilar Training and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01735331
Collaborator
(none)
30
Enrollment
1
Location
9
Duration (Months)
3.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of this study is determine vascular endothelial growth factor levels and angiogenesis/vascularity from hysteroscopic endometrial biopsies which taken from patients who has Recurrent Pregnancy Loss.The endometrial vascular endothelial growth factor levels will be measured by immunohistochemical staining methods due to office hysteroscopic endometrial biopsy after the menstruation at follicular phase of menstrual cycle.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This study is a prospective,observational,single-center study.Ethical approval was obtained from the Institutional Review Board.This study will be completed 30 patients with Habitual Abortus.

    Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1) antibody kits. All assays will be performed according to the manufacturer's instructions.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    30 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss
    Study Start Date :
    Nov 1, 2012
    Actual Primary Completion Date :
    Aug 1, 2013
    Actual Study Completion Date :
    Aug 1, 2013

    Arms and Interventions

    Arm Intervention/Treatment
    VEGF level

    VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
    control group

    Patients with Abnormal Uterine Bleeding

    Outcome Measures

    Primary Outcome Measures

    1. The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with Recurrent Pregnancy Loss [3 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with Recurrent Pregnancy Loss who accept to join the study.
    Exclusion Criteria:

    • Patients whose age of <18 and >45

    • Patients with have any pregnancy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Bagcilar Training and Research Hospital Istanbul Turkey

    Sponsors and Collaborators

    • Bagcilar Training and Research Hospital

    Investigators

    • Principal Investigator: TANER A. USTA, M.D., Bagcilar Training and Research Hospital,Istanbul,Turkey.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Bagcilar Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT01735331
    Other Study ID Numbers:
    • BEHGynObs-3
    First Posted:
    Nov 28, 2012
    Last Update Posted:
    Aug 7, 2015
    Last Verified:
    Aug 1, 2015
    Keywords provided by Bagcilar Training and Research Hospital
    Vascular endothelial growth factor, Recurrent Pregnancy Loss
    Additional relevant MeSH terms:
    Abortion, Spontaneous
    Fetal Death
    Abortion, Habitual
    Recurrence

    Study Results

    No Results Posted as of Aug 7, 2015